Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Faces Potentially Rough Ride In The Face Of Macroeconomic Headwinds

Revenue Grows But Profits Take A Hit At Bangladeshi Generics Firm

Executive Summary

Following a year of impressive business developments, economic developments such as a depreciating local currency threaten to knock Beximco off-course.

You may also be interested in...



Beximco Profit Tumble Continues Amid Hostile Macro Climate

Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.

Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line

The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation

Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel